Evidence map›Paper›PMID 33411035›Full record

ArticleEJNMMI radiopharmacy and chemistry2021

Implementation and validation of an in-house combined fluorescein/media-fill test to qualify radiopharmacy operators.

Cyril Fersing, Emmanuel Deshayes, Sarah Langlet, Laurence Calas, Vincent Lisowski, Pierre Olivier Kotzki

Abstract read
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Cyril FersingDepartment of Nuclear Medicine, Montpellier Cancer Institute (ICM), University of Montpellier, 208 avenue des apothicaires, 34298, Montpellier Cedex 5, France. cyril.fersing@icm.unicancer.fr.ORCID http://orcid.org/0000-0002-4455-4641
Emmanuel DeshayesDepartment of Nuclear Medicine, Montpellier Cancer Institute (ICM), University of Montpellier, 208 avenue des apothicaires, 34298, Montpellier Cedex 5, France.
Sarah LangletDepartment of Nuclear Medicine, Saint-Jean Hospital, Perpignan, France.
Laurence CalasDepartment of Nuclear Medicine, Montpellier Cancer Institute (ICM), University of Montpellier, 208 avenue des apothicaires, 34298, Montpellier Cedex 5, France.
Vincent LisowskiInstitut des Biomolécules Max Mousseron, UMR 5247, CNRS, Université de Montpellier, ENSCM, UFR des Sciences Pharmaceutiques et Biologiques, Montpellier Cedex, France.
Pierre Olivier KotzkiDepartment of Nuclear Medicine, Montpellier Cancer Institute (ICM), University of Montpellier, 208 avenue des apothicaires, 34298, Montpellier Cedex 5, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe purpose of this work was to design, validate and implement a media-fill test combined with fluorescein (MFT-F) for the specific qualification and training of radiopharmacy operators, in accordance with United States Pharmacopeia General Chapter 797 and European Good Manufacturing Practices. MFT-F was embedded in the quality management system of our radiopharmacy unit. Its validation involved fluorescein concentration choice, media growth promotion test and evaluation protocol controls (with or without intentional aseptic mistakes). Each operator was evaluated following a three-part evaluation form. Evaluation criteria related to garbing and hygiene, fluorescent contamination and bacteriological contamination (pre- and post-evaluation environment controls and MFT-F samples). Combined MFT-F allowed the assessment of aseptic compounding skills and non-contamination of the working area through a single evaluation. It was also designed to fit the constraints of radiopharmacy common practice related to radiation protection equipment and to the small volumes handled.

resultsA 0.01% fluorescein concentration was chosen to prepare MFT-F. Addition of fluorescein in the culture medium did not jeopardize its growth properties according to growth promotion test. Eleven operators were evaluated and carried out 3 MFT-F over 3 successive days. Pre- and post-evaluation bacteriological controls of every session showed no CFU of microbiological contaminant above 5. All operators validated the garbing and hygiene evaluation, with an average score of 92.7%. All operators validated the fluorescent contamination evaluation, with an average score of 29.4 out of 30. None of the MFT-F samples showed any visible bacterial growth after incubation.

conclusionsCombined MFT-F, as a part of a comprehensive sterile compounding training program, appeared as a convenient and promising tool to increase both the sterile compounding safety and awareness of radioactive contamination in radiopharmacy.

Indexed as

FluoresceinGood radiopharmacy practicesMedia-fill testOperators qualificationSterile compounding

Identifiers

PMID33411035
PMCPMC7790972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.